1159610-75-9

Upstream product

• 1159610-60-2 C₂₂H₂₇ClN₄O₆S 
• 4023-34-1 cyclopropanecarboxylic acid chloride 
• 1159610-59-9 C₁₇H₂₆N₄O₅ 
• 1159610-58-8 C₂₅H₂₈N₄O₇ 
• 1159610-57-7 C₂₄H₃₀N₄O₆ 
• 1159610-56-6 C₁₃H₂₁N₃O₃ 
• 1159610-55-5 C₁₃H₁₉N₃O₅ 
• 1159610-54-4 C₈H₁₁N₃O₃ 
• 1159610-53-3 C₁₆H₁₃N₃O₅ 
• 350-46-9 4-Fluoronitrobenzene 
• 1965-54-4 N-(2-hydroxyethyl)-4-nitroaniline 
• 100418-51-7 2-((4-nitrophenyl)amino)ethyl methanesulfonate 

Downstream Products

• 1159610-42-0 C₂₁H₂₁ClN₄O₄S 

Relevant academic research and scientific papers

FXA INHIBITORS WITH CYCLIC AMIDOXIME OR CYCLIC AMIDRAZONE AS P4 SUBUNIT, PROCESSES FOR THEIR PREPARATIONS, AND PHARMACEUTICAL COMPOSITIONS AND DERIVATIVES THEREOF

The present invention relates to novel oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone group, pharmaceutically acceptable salts thereof, methods for preparing the same and pharmaceutical compositions comprising the same. The oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone group or the pharmaceutically acceptable salts thereof can be effectively used for the treatment of thromboembolism and tumor as an anticoagulant based on the inhibition of factor Xa.

FXA INHIBITORS WITH CYCLIC AMIDOXIME OR CYCLIC AMIDRAZONE AS P4 SUBUNIT, PROCESSES FOR THEIR PREPARATIONS, AND PHARMACEUTICAL COMPOSITIONS AND DERIVATIVES THEREOF

The present invention relates to novel oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone group, pharmaceutically acceptable salts thereof, methods for preparing the same and pharmaceutical compositions comprising the same. The oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone group or the pharmaceutically acceptable salts thereof can be effectively used for the treatment of thromboembolism and tumor as an anticoagulant based on the inhibition of factor Xa.